SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register–based cohort study
2024

SARS-CoV-2 Infection and Risk of Demyelinating Diseases

Sample size: 9959818 publication 10 minutes Evidence: moderate

Author Information

Author(s): Scott Montgomery, Snieguole Vingeliene, Huiqi Li, Helena Backman, Ruzan Udumyan, Johan Jendeberg, Gunlög Rasmussen, Martin Sundqvist, Katja Fall, Ayako Hiyoshi, Fredrik Nyberg

Primary Institution: Örebro University

Hypothesis

Is SARS-CoV-2 infection associated with subsequent diagnoses of demyelinating diseases?

Conclusion

Hospital admission for COVID-19 is linked to an increased risk of both non-multiple sclerosis demyelinating diseases and multiple sclerosis.

Supporting Evidence

  • Hospital admission for COVID-19 was associated with a raised risk of subsequent non-multiple sclerosis demyelinating disease.
  • Only a small number of non-multiple sclerosis demyelinating disease diagnoses were associated with hospital admission for COVID-19.
  • 28 individuals were diagnosed with multiple sclerosis following hospital admission for COVID-19.

Takeaway

Getting really sick from COVID-19 might make you more likely to get certain brain diseases later on.

Methodology

The study followed all residents of Sweden aged 3–100 years from January 2020 to November 2022, excluding those with prior demyelinating diseases, and used Cox regression to assess risks.

Potential Biases

There may be shared susceptibility or surveillance bias affecting the results.

Limitations

The study's outcomes were based on hospital admissions, which may not capture all cases, and the small number of diagnoses raises questions about diagnostic accuracy.

Participant Demographics

The study included individuals aged 3 to 100 years, with a mix of genders and varying health statuses.

Statistical Information

P-Value

0.004 for non-multiple sclerosis demyelinating diseases; <0.001 for multiple sclerosis

Confidence Interval

2.35 (1.32–4.18) for non-multiple sclerosis; 2.48 (1.70–3.61) for multiple sclerosis

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/braincomms/fcae406

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication